High-dose acyclovir and intravenous immune globulin reduce the incidence of CMV disease after liver transplantation
| Autor: | Ozgur Yagmur, Burt R. Meyers, Charles M. Miller, Keiji Kishikawa, Sukru Emre, Myron Schwartz, Eytan Mor, Patricia A. Sheiner |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Adult
Graft Rejection Male Nephrology medicine.medical_specialty Allergy medicine.medical_treatment Congenital cytomegalovirus infection Acyclovir Liver transplantation Gastroenterology Internal medicine medicine Humans Aged Transplantation Hematology biology business.industry Incidence (epidemiology) Immunoglobulins Intravenous virus diseases Middle Aged medicine.disease Liver Transplantation Regimen Cytomegalovirus Infections Immunology biology.protein Female Antibody business Immunosuppressive Agents |
| Zdroj: | Transplant International. 8 |
| ISSN: | 0934-0874 1432-2277 |
| DOI: | 10.1007/bf00344426 |
| Popis: | We attempted to prevent cytomegalovirus (CMV) disease in liver transplant (LTx) recipients by means of a combined prophylaxis regimen consisting of high-dose acyclovir (HDA) and immune globulin (IVIG). In 259 consecutive patients, HDA was given for 3 months post-LTx; recipients seronegative for CMV also received IVIG. The previous 94 patients comprised our control group; in this group, low dose acyclovir was given to prevent herpes, and prophylaxis of CMV consisted of IVIG given only to seronegative recipients of seropositive donors. The overall incidence of CMV disease was lower in the HDA group (10.8%) than in the control group (27.6%); (P < 0.001). The CMV disease rate associated with primary exposure was 26.3% in the HDA group and 83.3% in the control group (P < 0.001). The incidence of CMV disease occurring after acute rejection was 9.5% in HDA patients and 24.6% in controls (P < 0.005) The HDA protocol was associated with a trend toward a lower incidence of CMV in patients requiring OKT3 therapy (16.7% vs 29%). High-dose acyclovir/IVIG thus reduces the incidence of CMV disease in seronegative recipients after LTx and lowers the risk of CMV disease associated with therapy for rejection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|